Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | NOS3 | P29474 | 2/20 | 0.51 |
| ▸ | NOS1 | P29475 | 2/20 | 0.51 |
| ▸ | NOS2 | P35228 | 2/20 | 0.51 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | PTPRA | P18433 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429691 | 1.00 | ALPI (0.51) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL43104 | 1.00 | ALPI (0.51) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL8977587 | 1.00 | ALPI (0.51) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL8126535 | 0.98 | NOS3 (0.50) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL598438 | 0.86 | GRM8 (0.48) | NOS3NOS1NOS2GRIA2GRM8 | |
| SCHEMBL10416252 | 0.86 | GRM8 (0.53) | TSHRALDH1A1GRM8GRM4CYP1A2 | |
| SCHEMBL29500946 | 0.86 | GRM8 (0.53) | TSHRALDH1A1GRM8GRM4CYP1A2 | |
| SCHEMBL27977862 | 0.86 | GRIA2 (0.45) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL13660654 | 0.85 | PKM (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL3096665 | 0.85 | ALDH1A1 (0.55) | TSHRALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1777 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| US-12577575-B2 | Methods and compositions for promoting non-natural amino acid-containing protein production | AMBRX, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4644570-A1 | HELICASE MUTANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN HIGH-THROUGHPUT SEQUENCING | BGI Shenzhen (CN) | 2025-11-05 | — | — | EP | claimed |
| US-12404512-B2 | Method for optimizing antibody expression | AMBRX, INC. (US) | 2025-09-02 | — | — | US | claimed |
| EP-3788149-B1 | A METHOD FOR OPTIMIZING ANTIBODY EXPRESSION | AMBRX INC (US) | 2025-08-27 | — | — | EP | claimed |
| US-12377294-B2 | Anti-CD3 antibody folate bioconjugates and their uses | AMBRX, INC. (US) | 2025-08-05 | — | — | US | claimed |
| US-20250243472-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-07-31 | — | — | US | claimed |
| CN-119340400-B | Composite current collector and preparation method thereof | 扬州纳力新材料科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | claimed |
| WO-2008031016-A2 | HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | WO | claimed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | claimed |
| WO-2005122379-A2 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | claimed |
| EP-0646596-B1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1999-05-26 | — | — | EP | claimed |
| EP-0646595-B1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1998-11-04 | — | — | EP | claimed |
| US-5623049-A | FLEXIBLE ANTISENSE AGENTS COMPRISING OLIGONUCEOTIDES HAVING THE (DEOXY)RIBOSE BACKBONE REPLACED BY AN OLIGOPEPTIDE; PROTEASE- AND NUCLEASE-RESISTANT; VIRICIDES; ATTACHED TO CARRIERS ABLE TO PENETRATATE IN CELLS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-04-22 | — | — | US | claimed |
| EP-0700928-A1 | Nucleic acid-binding oligomers for therapy and diagnostics | BAYER AG (DE) | 1996-03-13 | — | — | EP | claimed |
| EP-0646595-A1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1995-04-05 | — | — | EP | claimed |
| EP-0646596-A1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1995-04-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | ALPI 3006/4885PKM 4240/4885PTGS1 3492/4885 |
| US-12377294-B2 | Anti-CD3 antibody folate bioconjugates and their uses | FOLR2, FOLR1, CD2 | ALPI 1217/4885PKM 4371/4885PTGS1 4505/4885 |
| US-12577575-B2 | Methods and compositions for promoting non-natural amino acid-containing protein production | AARS1, NSUN3, UPF1 | ALPI 2459/4885PKM 2865/4885PTGS1 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.